These include pancreatitis, gallbladder inflammation, kidney complications, and in rare cases, thyroid-related tumors
In the UK, Wegovy is licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for chronic weight management in adults with an initial BMI of 30 kg/m (obesity) or 27 kg/m (overweight) in the presence of at least one weight-related comorbidity, when used alongside a reduced-calorie diet and increased physical activity
Injecting too early increases the risk of side effects without speeding up results
Obici S, Feng Z, Morgan K, Stein D, Karkanias G, Rossetti L: Central administration of oleic acid inhibits glucose production and food intake
A 2024 study led by University of Pennsylvania psychologist Thomas A
Found a 2.19 times higher risk of developing NAION for patients prescribed weekly semaglutide (Ozempic, Wegovy)